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Proton MRS of the Unilateral Substantia Nigra in the
Human Brain at 4 Tesla: Detection of High GABA
Concentrations
Gu¨lin O¨z,1* Melissa Terpstra,1 Ivan Tka´cˇ,1 Pratibha Aia,2 Jodi Lowary,2 Paul J. Tuite,2
and Rolf Gruetter1,3
Parkinson’s disease (PD) is characterized by loss of dopami-
nergic neurons in the substantia nigra (SN), the cause of which
is unknown. Characterization of early SN pathology could prove
beneﬁcial in the treatment and diagnosis of PD. The present
study shows that with the use of short-echo (5 ms) Stimulated-
Echo Acquisition Mode (STEAM) spectroscopy and LCModel, a
neurochemical proﬁle consisting of 10 metabolites, including
-aminobutyric acid (GABA), glutamate (Glu), and glutathione
(GSH), can be measured from the unilateral SN at 4 tesla. The
neurochemical proﬁle of the SN is unique and characterized by
a fourfold higher GABA/Glu ratio compared to the cortex, in
excellent agreement with established neurochemistry. The
presence of elevated GABA levels in SN was validated with the
use of editing, suggesting that partial volume effects were
greatly reduced. These ﬁndings establish the feasibility of ob-
taining a neurochemical proﬁle of the unilateral human SN by
single-voxel spectroscopy in small volumes. Magn Reson
Med 55:296–301, 2006. © 2006 Wiley-Liss, Inc.
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Parkinson’s disease (PD) is characterized by loss of dopa-
minergic neurons in the substantia nigra (SN), but its eti-
ology remains poorly understood. Mitochondrial dysfunc-
tion, oxidative stress, and glutamate (Glu) excitotoxicity
may play roles in the pathogenesis of sporadic PD (1).
However, evidence implicating these factors in PD has
been limited to cell culture, animal model, and postmor-
tem tissue studies. In vivo, positron emission tomography
(PET) and single photon emission computed tomography
(SPECT) have been used to distinguish patients with PD
from normal controls (2), based on measures obtained from
the striatum. Other in vivo methods are needed to assess
the pathology of PD directly in the SN.
Neuronal loss of the SN can in principle be assessed by
MRI (e.g., as indicated by atrophy of the structure). Inter-
estingly, conventional MR images of patients with idio-
pathic PD are usually normal (3). A narrowing of the SN
pars compacta (SNpc), where most neuronal loss occurs in
PD, has been reported in studies using MRI, albeit not
consistently (4–8). Reduced water T2 values have been
observed in the SN, probably due to iron accumulation,
with signiﬁcant overlap between patients and controls (9).
Recently developed inversion recovery techniques appear
to be useful for visualizing nigral atrophy by utilizing a
combination of two pulse sequences to suppress gray and
white matter, respectively (10).
Magnetic resonance spectroscopy (MRS) potentially can
detect pathogenic markers of PD that reﬂect metabolic,
excitotoxic, and oxidative insults that likely occur before
irreversible structural damage, such as changes in lactate
(Lac), Glu, and glutathione (GSH) levels (11). Previous
MRS studies of PD mostly reported ratios of NAA, creatine
(Cr), and choline-containing compounds (Cho) (12,13).
Decreased NAA/Cho or NAA/Cr ratios in PD were found
in some studies (12,13). Most of these studies investi-
gated the striatum or cortex. Because of its very small
volume, the SN has been studied infrequently. Rela-
tively large volumes of interest (VOIs; 3.4–8 ml) around
the SN were employed in the few MRS studies that
examined the unilateral or bilateral SN, resulting in
partial volume effects (14–16). Since PD characteristi-
cally is an asymmetric condition, acquiring data from
smaller VOIs encompassing the SN contralateral to the
clinically ﬁrst and more severely affected side of pa-
tients with PD is of interest.
In addition to its small size, other challenges of measur-
ing MR spectra the SN include its location in the midbrain
and its high iron content. Broader lines relative to other
brain regions are expected in the SN, even with the use of
automated shimming routines. However, increased sensi-
tivity potentially can be achieved in the SN by utilizing a
high magnetic ﬁeld and an efﬁcient volume coil. Spectra
with higher information content can facilitate quantitation
of neurotransmitters, such as Glu and -aminobutyric acid
(GABA), and antioxidants, such as GSH, making it feasible
to test pathogenic theories regarding PD.
The aims of the current study were to 1) demonstrate
the feasibility of obtaining short-echo 1H MR spectra at
4 T in small volumes encompassing the unilateral SN in
healthy volunteers and patients with PD, and 2) deter-
mine which metabolites can be reliably quantiﬁed in these
spectra.
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MATERIALS AND METHODS
Patients and Control Subjects
Ten patients with mild–moderate PD (six females and four
males, 59  10 years old, mean  SD) and 11 age-matched
healthy volunteers (seven females and four males, 59  8
years old) were studied using stimulated-echo acquisition
mode (STEAM) spectroscopy in 2.2-ml volumes centered on
the unilateral SN. The Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS) score for the patients was 27  9 (mean 
SD), and the disease duration after diagnosis was 2.3  1.5
years (mean  SD). The patients were kept off their antipar-
kinsonian medications for at least 12 hr prior to the MR scan.
Additionally, ﬁve healthy volunteers (two females and
three males, 28  3 years old) studied with GABA editing
were compared with four healthy volunteers (two females
and two males, 29  10 years old) studied with STEAM
spectroscopy in 5.3-ml volumes encompassing the bilat-
eral SN. All of the subjects were scanned after informed
consent was obtained using procedures approved by the
Institutional Review Board: Human Subjects Committee of
the University of Minnesota.
STEAM Spectroscopy
All studies were performed on a 4 tesla, 90-cm bore mag-
net (Oxford Magnet Technology, Oxford, UK) with an
INOVA console (Varian, Palo Alto, CA, USA) and a stan-
dard body gradient coil (Sonata, Siemens, Erlangen, Ger-
many). A TEM volume coil was used as the NMR trans-
ceiver (17). After the subject was positioned in the magnet,
transverse multislice images were obtained with a rapid
acquisition with relaxation enhancement (RARE) se-
quence (repetition time (TR)  4 s, echo train length  8,
echo spacing  15 ms, echo time (TE)  60 ms, seven
slices, two averages) for selection of the VOI. Localization
of 1H MR spectra was achieved using ultrashort-echo
STEAM spectroscopy with TE 5 ms, mixing time (TM)
42 ms, and TR  4.5 s (18). Water suppression was
achieved using eight variable power RF pulses with opti-
mized relaxation delays (VAPOR) that were interleaved
with outer volume suppression to improve localization
performance (18). All ﬁrst- and second-order shims were
adjusted using Fast Automatic Shimming Technique by
Mapping Along Projections (FASTMAP) with echo-planar
readout (19). Spectra were acquired from a 1.3  1.3 
1.3 cm3 volume (2.2 ml) to encompass the unilateral SN,
and a 3.5  1.5  1.0 cm3 volume (5.3 ml) to encompass
the SN bilaterally. The SN contralateral to the more af-
fected side was selected in patients. Unavoidably, the
2.2-ml VOI contained parts of other brain structures, such
as the red nucleus, subthalamic nucleus, and cerebral pe-
duncle. However, this volume was selected as the smallest
cubic volume around the SN because this structure ex-
tends rostrocaudally for 12  2 mm in the human brain
(20). In each VOI the unsuppressed water signal was ob-
tained as a quantitation reference. The total time each
volunteer spent in the magnet did not exceed 1 hr.
Spectral Quantitation
The contribution of individual metabolites to the in vivo
spectrum was quantiﬁed using LCModel (21). The follow-
ing 20 metabolites were included in the basis set: Alanine
(Ala), aspartate (Asp), glycerophosphorylcholine (GPC),
phosphorylcholine (PCho), creatine (Cr), phosphocreatine
(PCr), GABA, glucose (Glc), glutamine (Gln), Glu, GSH,
myo-inositol (myo-Ins), lactate (Lac), N-acetylaspartate
(NAA), N-acetylaspartylglutamate (NAAG), phospho-
rylethanolamine (PE), scyllo-inositol (scyllo-Ins), taurine
(Tau), and macromolecules (MM). The model metabolite
spectra were obtained by simulation (18) using previously
reported chemical shifts and coupling constants (22). The
macromolecule pattern was obtained by averaging inver-
sion recovery spectra from the right and left unilateral SNs
(VOI  2.2 ml) of ﬁve healthy subjects. For this measure-
ment, the STEAM parameters were optimized to null the
metabolite resonances (TR 2 s, inversion time 0.675 s).
Since the signal-to-noise ratio (SNR) in this averaged spec-
trum was low, the macromolecule pattern was similarly
obtained from the occipital gray matter (VOI 8 ml) of ﬁve
additional healthy subjects. Spectra were quantiﬁed by
including both the occipital gray matter and the SN MM in
the LCModel basis set for comparison. Quantiﬁcation of
the in vivo metabolite signals was based on the unsup-
pressed water signal obtained from the same voxel (23),
assuming a water content of 82% (24).
Assessment of Reliability in Metabolite Concentrations
and Statistical Analysis
The criteria for selecting the reliable metabolite concentra-
tions were based on the Crame´r-Rao lower bounds (CRLB),
which are estimates of the %SD of the ﬁt for each metab-
olite (21). Only results with a CRLB  50% were included
in the analysis. Concentrations with CRLB  50% were
classiﬁed as not detected. Only those metabolites that had
a CRLB below 50% in at least half of the spectra were
reported. If the covariance between two metabolites was
consistently high (correlation coefﬁcient  –0.5), such as
in the case of Cr and PCr, their sum was reported rather
than their individual values.
The concentrations of metabolites in controls and pa-
tients were compared using the two-tailed, unpaired Stu-
dent’s t-test, without a correction for multiple compari-
sons.
GABA Editing
To verify the GABA concentration obtained by STEAM
spectroscopy, GABA editing was utilized. To provide suf-
ﬁcient SNR for edited spectroscopy, VOIs of 5.3 ml that
encompassed the SN bilaterally were selected in healthy
volunteers. MEGA-Point Resolved Spectroscopy (MEGA-
PRESS) difference editing (TE  68 ms, TR  4.5 s) was
optimized for detection of the 4CH2 resonance of GABA
(NH2-
4CH2-
3CH2-
2CH2-
1CO2H) at 3.0 ppm via the coupled
3CH2 resonance (1.9 ppm) with minimized signal contam-
ination from MM, as described previously (25). Speciﬁ-
cally, the offset of the editing pulse (20 ms Gaussian)
alternated between 2.0 ppm (J-evolution suppressed, “on”)
and 1.4 ppm (J-evolution unsuppressed, “off”) symmetri-
cally around the coupling partner (1.7 ppm) of the 3.0 ppm
MM resonance. Shifting the editing pulse from its ideal
offset (1.9 ppm) to 2.0 ppm minimized loss of edited signal
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via partial excitation of the 3CH2 resonance by the “off”
pulse. VAPOR water suppression and outer volume sup-
pression preceded the MEGA-PRESS sequence. Each free
induction decay (FID) (number of excitations (NEX)  1)
was frequency- and phase-corrected prior to summation as
described previously (26). B0 drift was 7 Hz, which en-
sured negligible MM contamination. All MEGA-PRESS
pulse powers were calibrated on-resonance for water in a
cerebrospinal ﬂuid (CSF)-free subvolume of interest,
where the water signal was sufﬁciently stable. Under this
editing scheme, the 2CH of Glu (3.74 ppm), Gln
(3.75 ppm), and GSH (3.77 ppm) contributed a combined
resonance via their coupling partners (2.0–2.2 ppm)
within the bandwidth of the editing pulse (2.0 ppm). NAA
was used as an internal reference for quantitation of edited
spectra as follows: An accordingly line-broadened MEGA-
PRESS edited spectrum acquired from a phantom contain-
ing GABA (5 mM) and NAA (1 mM) was used to calibrate
relative peak heights for quantitation of GABA. The NAA
singlet at 2.01 ppm contributed to the edited spectrum via
inversion on alternate scans. In vivo NAA concentration
was set to that measured using LCModel analysis of cor-
responding short-echo STEAM spectra. Similarly, an ed-
ited spectrum from a phantom containing Glu (6 mM), Gln
(2 mM), GSH (2 mM), and NAA (12 mM) was used to
calibrate relative peak heights for quantitation of the com-
bined Glu, Gln, and GSH resonance near 3.8 ppm. On the
basis of prior studies (26), T2 relaxation effects were as-
sumed to have a negligible inﬂuence on quantitation.
RESULTS
Despite challenges in shimming and broad intrinsic line-
widths relative to other brain areas, spectral quality that
permitted assessment of the neurochemical proﬁle of the
SN was achieved in 2.2-ml volumes in single subjects.
Spectral quality in patients with early PD and controls was
similar (Fig. 1), based on the full width at half maximum
(FWHM; 13.3  2.1 Hz (mean  SD) in controls, 13.5 
2.2 Hz in patients, P  0.9) and SNR values (6.5  0.8 in
controls, 6.0  1.2 in patients, P  0.3) determined by
LCModel. Similarly, the reliability of metabolite quantiﬁ-
cation with LCModel was comparable between the two
groups (Fig. 2; see relative error bars in the patient and
control groups). Of the 10 metabolites that met our criteria
for reliable quantiﬁcation (see Materials and Methods),
four were quantiﬁed with a median CRLB (including all 21
spectra in the median determination)  10% (NAA 
NAAG, Cr PCr, and GPC PCho (hereafter referred to as
NAA, Cr, and Cho, respectively), and myo-Ins), two me-
tabolites with a median CRLB of 30% (Glu and GSH),
and three metabolites with a median CRLB of 40%
(GABA, Glc  Tau, and scyllo-Ins) when the high-SNR
gray matter MM spectrum was used in the LCModel basis
set. The median CRLB for Lac was 50%. Using the SN MM
spectrum did not change the neurochemical pattern; how-
ever, Lac was only quantiﬁed (CRLB  50%) in seven, and
GABA in 10 of 21 spectra acquired from a 2.2-ml VOI in
this case.
When the neurochemical proﬁles of the two groups were
compared, Glu, NAA, and GSH showed a trend to de-
crease, and Cho showed a trend to increase in patients
with PD (P-values obtained using gray matter and SN MM
patterns were in the range of 0.1–0.2 for all of these me-
tabolites; Fig. 2a). To ensure that the quality of individual
spectra was sufﬁcient to accurately assess these trends,
averaged spectra from the patient and control groups were
quantiﬁed identically and showed the same trends (Fig.
2b).
Two of the concentrations determined in SN (high
GABA and low Glu) were very different from those in the
occipital cortex (P  0.00001; Fig. 2a). To investigate
whether these differences were an effect of linewidth and
low SNR, the occipital cortex spectra of four averages were
line-broadened and appropriate amounts of noise were
added to these spectra to mimic the spectral quality of the
SN spectra (linewidth and SNR). Glu concentrations esti-
mated with LCModel showed a trend to decrease when the
linewidth was increased and SNR decreased, indicating
that the reported Glu levels in the SN may be underesti-
mated. GABA became undetectable (CRLB  50%) in
about half of the spectra, indicating that the high values
observed in the SN were not a result of broad lines and low
SNR. Overall, the changes did not explain the drastically
(fourfold) different GABA/Glu ratios observed in SN vs.
cortex.
To further substantiate the presence of an elevated
GABA/Glu ratio, averaged spectra from both subject
groups were inspected (Fig. 3). Clearly, the peak at
2.32 ppm in the averaged spectrum is between the
2.34 ppm 4CH2 resonance of Glu and the 2.28 ppm
2CH2
resonance of GABA, indicating that Glu and GABA con-
tribute comparably to the spectrum.
FIG. 1. Averaged 1H MR spectra (TE 5 ms, TR 4.5 s, NEX 400
for each subject) acquired from 2.2-ml volumes that encompass the
SN of (a) 11 healthy volunteers and (b) 10 patients with PD. The
typical VOI is shown in the T2-weighted image.
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To further verify the quantiﬁcation of GABA, MEGA-
PRESS editing was utilized in VOIs that encompassed the
SN bilaterally (Fig. 4). The edited GABA resonance
(3.0 ppm) was detected in all ﬁve volunteers scanned. The
in vivo GABA concentration was estimated from each of
the ﬁve edited spectra relative to 11 	mol/g NAA, the
average NAA concentration measured from STEAM spec-
tra acquired in 5.3-ml voxels. The GABA concentration
measured using STEAM (2.4  0.4 	mol/g, mean  SD) in
four healthy volunteers from the same VOI was in excel-
lent agreement with the editing (2.4  0.5 	mol/g). At 4 T,
resonances from Glu, Gln, and GSH coedited with and
were well resolved from GABA (Fig. 4). The sum of their
concentrations in vivo was estimated at 8.7 	mol/g from
the combined edited resonance at 3.76 ppm, in good agree-
ment with the 8.4 	mol/g of Glu  Gln  GSH measured
from the same VOI using STEAM and LCModel analysis.
To compare edited GABA quantitation in the SN with
that in the occipital cortex, we acquired an edited GABA
spectrum from a 27-ml VOI in one volunteer (Fig. 4b).
Relative to the summed SN spectrum acquired from a
5.3-ml VOI and averaged over ﬁve volunteers, the sensi-
tivity in this spectrum was more than doubled. Indeed, the
cortical GABA peak was much smaller than the SN GABA
peak and corresponded to a GABA concentration of
1 	mol/g, in agreement with literature (25).
DISCUSSION
We have demonstrated the feasibility of obtaining short-
echo STEAM spectra and assessing the neurochemical
proﬁle from small volumes in the midbrain encompassing
the SN, an area of interest in PD. Upon LCModel ﬁtting of
spectra from healthy volunteers and patients with PD, 10
metabolites were quantiﬁed reliably and included in the
neurochemical proﬁle. This proﬁle was unique to the SN
region with high GABA and low Glu levels. The high
GABA concentration was veriﬁed by editing for this me-
tabolite, since in short-echo STEAM spectra resonances
from GABA are overlapped with resonances from other
neurochemicals, such as Cr and Glu.
LCModel ﬁtting of individual STEAM spectra (VOI 
2.2 ml) resulted in the same neurochemical pattern ob-
tained by ﬁtting of averaged spectra (Fig. 2), indicating
adequate spectral quality for reliable quantiﬁcation in in-
dividual volunteers. With the use of this small VOI, partial
volume effects were reduced compared to previous MRS
studies of the SN. Better localization in the SN potentially
can be achieved by utilizing oblique voxels, as well as
multiple spatial saturation planes to deﬁne the noncuboi-
dal shape of the SN, as recently proposed (27). However,
uncertainties pertaining to the deﬁnition of the borders of
SN in T2-weighted images exist (8). The 2.2-ml volume we
chose included the entire structure beyond these uncer-
tainties.
The reduction in partial volume effects was further sup-
ported by the high GABA and low Glu levels detected in
the neurochemical proﬁle obtained from both individual
and averaged spectra (Figs. 2 and 3). Note that the GABA
moiety of homocarnosine may partially contribute to the
free GABA signal (25), since the homocarnosine concen-
FIG. 3. Validation of high GABA concentrations in averaged spectra
from healthy controls (N  11, VOI  2.2 ml). Below the averaged
spectrum are shown the contributions of GABA and Glu, as well as
their sum, to the in vivo spectrum as determined by LCModel. The
2.32 ppm peak clearly lines up with the summed contributions of
GABA and Glu.
FIG. 2. Metabolite concentrations determined by LCModel ﬁtting of
(a) individual and (b) averaged STEAM spectra from the SN of
controls and patients with PD (VOI  2.2 ml, gray matter macro-
molecule pattern utilized). Also shown are the GABA and Glu con-
centrations obtained in the occipital cortex (VOI  8 ml) of
10 healthy volunteers. The errors shown in a are SDs, and in b CRLB
obtained from LCModel. * P  0.00001 occipital cortex vs. SN of
both controls and patients.
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tration is about one-third that of GABA in the cortex.
However, the homocarnosine-to-GABA concentration ra-
tio in the SN is approximately half of that in the cortex
(28), and therefore this contribution is expected to be
smaller in the SN. High GABA levels in the SN have been
documented in postmortem human and animal brains
(28–30). The absolute GABA concentration we obtained
from the 2.2-ml VOI (3.2 	mol/g) was less than that mea-
sured in the autopsied human brain (5–6 	mol/g) (28,29),
likely because of the well-known postmortem increase of
GABA in the brain. On the other hand, the ratio of GABA
levels in SN vs. cortex (3) observed in the current study
were the same as in postmortem brain (28–30).
The difﬁculty of GABA quantitation was underscored by
the effect of including different macromolecule spectra in
the LCModel basis. Inclusion of the noisy SN macromole-
cule pattern resulted in reduced reliability of quantitation
of this neurotransmitter. Nevertheless, the GABA quanti-
ﬁcation by STEAM spectroscopy was substantiated by
MEGA-PRESS editing for GABA. Based on the edited
GABA spectrum acquired from a 27-ml volume in the
occipital cortex (Fig. 4b), the low (1 	mol/g) GABA con-
centrations typical of other brain regions would not have
been detected in 5.3-ml volumes in individual edited spec-
tra (NEX  512). The fact that GABA was detected in all
ﬁve edited spectra is evidence of an elevated GABA con-
centration in the region encompassing the SN. In addition,
the GABA concentrations quantiﬁed from edited and
STEAM spectra were very similar, indicating that LC-
Model analysis of short-echo STEAM spectra acquired
from the SN at 4 T provides accurate quantitation of
GABA, despite overlapping resonances. The GABA con-
centration acquired from the 5.3-ml VOI (2.4 	mol/g) was
less than what was measured in the 2.2-ml VOI (3.2 	mol/
g), as was the case with all other metabolites. This was
expected due to the higher partial volume effect from CSF
in the center of this larger volume. The 2.2-ml volume did
not contain CSF based on images. Additionally, based on a
series of water signals acquired from this volume at differ-
ent TE values (5–1200 ms), we did not detect a long T2
component of the exponential decay of the water signal
with increasing TE, which also indicates a negligible CSF
contribution.
The few published MRS studies of the SN in PD utilized
larger volumes encompassing the SN (3.4–8 ml). Choe et
al. (14) observed a laterality of the NAA/Cr ratio between
asymptomatic and symptomatic sides of SN in PD, and
Baik et al. (16) detected a decrease in NAA/Cho after
thalamotomy. When O’Neill et al. (15) compared the SN
spectra of patients and controls, they observed decreased
Cr in patients with bilateral symptoms of at least moderate
severity. With the limited number of patients scanned in
the current study, we observed trends in Glu, NAA, GSH,
and Cho in patients relative to controls. These trends were
not a result of different degrees of spectral quality
achieved in the patient and control groups, since similar
linewidths and SNRs were observed in the two groups. In
this preliminary account, the patient group was scanned
merely to establish feasibility, and the only criterion for
inclusion in the study was a diagnosis of PD within the last
5 years. Therefore, heterogeneity in this small patient
group may have obscured more decisive observations.
PD has a preclinical period of 4–6 years (3) and early
detection of this disorder is of high interest in light of the
neuroprotective agents that are being tested in clinical
trials (31). Identiﬁcation of pathogenic markers of PD in
the SN could not only enable early detection of this dis-
ease, but could also improve our understanding of the
causes of neuronal loss in this region and aid in monitor-
ing the effects of potential neuroprotective agents. The
FIG. 4. MEGA-PRESS edited spectra (TE  68 ms, TR  4.5 s)
acquired from (a) an in vivo VOI of 5.3 ml (NEX  512 in each
subject, averaged over ﬁve subjects) encompassing the SN, illus-
trated on T2-weighted image; (b) an in vivo VOI of 27 ml (3  3 
3 cm3) located in the occipital cortex (NEX 512 in one subject) and
accordingly line-broadened; (c) a phantom containing 6 mM Glu,
2 mM Gln, 2 mM GSH, and 12 mM NAA (NEX  512, VOI  5.3 ml)
and accordingly line-broadened; and (d) a phantom containing
5 mM GABA and 1 mM NAA (NEX  512, VOI  5.3 ml) and
accordingly line-broadened. The spectra were scaled based on the
NAA peak height and concentration.
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potential of MRS in this area is further underlined by
anticipated increases in sensitivity. Thus, the utilization of
even higher magnetic ﬁelds is expected to enable further
reductions of the VOI and to increase the sensitivity to
detect potential biochemical changes associated with neu-
ronal loss in the SNpc. For example, the use of a 7 tesla
magnet along with a PRESS-type sequence instead of
STEAM can result in an up to fourfold sensitivity increase
in the same VOI. Alternatively, the sensitivity in the cur-
rent study potentially can be reached in VOIs of 0.5–0.6
ml.
In conclusion, single-voxel spectroscopy of the unilat-
eral human SN is feasible in both healthy volunteers and
patients with PD. This technique provides an in vivo neu-
rochemical proﬁle that includes neurotransmitter (Glu and
GABA) and antioxidant (GSH) levels that are in excellent
agreement with neurochemistry literature.
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